Developer of a medical drug designed to minimize the chances of brain injuries arising out of a stroke. The company's drug is focused on a new acute stroke therapy that identifies underlying factors and symptoms of stroke, enabling patients to minimize brain damage in different types of stroke.
Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
---|---|---|---|---|---|---|
3. Later Stage VC | 16-Dec-2016 | $651K | 00000 | Completed | Generating Revenue | |
2. Accelerator/Incubator | 02-Sep-2016 | Completed | Generating Revenue | |||
1. Corporate | 01-Jan-2007 | Completed | Startup |
Name | Title | Board Seat | Contact Info |
---|---|---|---|
Lars Edvinsson | Founder, Chief Scientific Officer & Board Member |
Name | Representing | Role | Since |
---|---|---|---|
Lars Edvinsson | Edvince | Founder, Chief Scientific Officer & Board Member | 000 0000 |
Per Antonsson Ph.D | Almi Invest | Board Member | 000 0000 |
Sarah Fredriksson Ph.D | Edvince | Board Member | 000 0000 |
Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
---|---|---|---|---|---|
Almi Invest | Venture Capital | Minority | 000 0000 | 000000 0 | |
LMK Forward | Venture Capital | Minority | 000 0000 | 000000 0 | |
Swedish Growth Fund | Venture Capital | Minority | 000 0000 | 000000 0 | |
SmiLe Incubator | Accelerator/Incubator | Minority | 000 0000 | 000000 0 | |
Krankajen Group | Corporation | Minority | 000 0000 | 000000 0 |